Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Martin Holst Lange, CSO & EVP of research & development at Novo Nordisk, discusses competition and the Danish company's ...

The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater ...

The number of people who reported experiencing constant thoughts about food declined by 46% after starting treatment with ...

Novo Nordisk's Wegovy will soon come in a pill form that's as effective as with a needle. A new study shows Wegovy taken once ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...